Login / Signup

Endoglin inhibitor TRC105 with or without bevacizumab for bevacizumab-refractory glioblastoma (ENDOT): a multicenter phase II trial.

Manmeet S AhluwaliaLisa R RogersRekha ChaudharyHerbert NewtonAhmad OzairAtulya Aman KhoslaAndrew B NixonBonne J AdamsBen K SeonDavid M PeereboomCharles P Theuer
Published in: Communications medicine (2023)
Single-agent TRC105 lacks activity in bevacizumab-refractory GBM, possibly secondary to upregulated VEGF-A expression. Meaningful mOS in bevacizumab+TRC105 cohort warrants further trials to investigate efficacy of combination therapy.
Keyphrases
  • combination therapy
  • metastatic colorectal cancer
  • poor prognosis
  • endothelial cells
  • quantum dots
  • clinical trial
  • binding protein
  • room temperature
  • gold nanoparticles
  • double blind
  • placebo controlled